Intercept Pharmaceuticals Inc (ICPT): Mark Pruzanski , CEO & President of Intercept Pharmaceuticals Inc sold 35,000 shares on Sep 20, 2016. The Insider selling transaction was reported by the company on Sep 22, 2016 to the Securities and Exchange Commission. The shares were sold at $165.00 per share for a total value of $5,775,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Aug 2, 2016, Rachel Mcminn (Chief Strategy Officer) sold 125 shares at $176.57 per share price.On Jul 7, 2016, Barbara Gayle Duncan (Chief Accounting Officer) sold 146 shares at $145.11 per share price.Also, On Jul 7, 2016, David Shapiro (CMO and EVP – Development) sold 163 shares at $145.11 per share price.On Jul 7, 2016, Mark Pruzanski (CEO & President) sold 714 shares at $145.11 per share price.
Intercept Pharmaceuticals Inc: On Thursday, Sep 22, 2016 heightened volatility was witnessed in Intercept Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $169.68 and hit $171.2 on the upside , eventually ending the session at $170.47, with a gain of 1.00% or 1.69 points. The heightened volatility saw the trading volume jump to 3,90,635 shares. The 52-week high of the share price is $217.99 and the company has a market cap of $4,215 M . The 52-week low of the share price is at $89.76.
Company has been under the radar of several Street Analysts.Intercept Pharmaceuticals Inc is Downgraded by Laidlaw to Sell while Lowering the Price Target of the company shares to $ 105 from a previous price target of $345 . Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Aug 5, 2016.Intercept Pharmaceuticals Inc is Initiated by Cantor Fitzgerald to Sell and the brokerage firm has set the Price Target at $58. The Rating was issued on Jul 6, 2016.
Intercept Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Companys product candidate obeticholic acid (OCA) is a bile acid analog a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.